Abstract:Osteoarthritis (OA) is the most common cause of disability worldwide among the elderly. Alarmingly, the incidence of OA in individuals less than 40 years of age is rising, likely due to the increase in obesity and post-traumatic osteoarthritis (PTOA). In recent years, due to a better understanding of the underlying pathophysiology of OA, several potential therapeutic approaches targeting specific molecular pathways have been identified. In particular, the role of inflammation and the immune system has been increasingly recognized as important in a variety of musculoskeletal diseases, including OA. Similarly, higher levels of host cellular senescence, characterized by cessation of cell division and the secretion of a senescence-associated secretory phenotype (SASP) within the local tissue microenvironments, have also been linked to OA and its progression. New advances in the field, including stem cell therapies and senolytics, are emerging with the goal of slowing disease progression. Mesenchymal stem/stromal cells (MSCs) are a subset of multipotent adult stem cells that have demonstrated the potential to modulate unchecked inflammation, reverse fibrosis, attenuate pain, and potentially treat patients with OA. Numerous studies have demonstrated the potential of MSC extracellular vesicles (EVs) as cell-free treatments that comply with FDA regulations. EVs, including exosomes and microvesicles, are released by numerous cell types and are increasingly recognized as playing a critical role in cell–cell communication in age-related diseases, including OA. Treatment strategies for OA are being developed that target senescent cells and the paracrine and autocrine secretions of SASP. This article highlights the encouraging potential for MSC or MSC-derived products alone or in combination with senolytics to control patient symptoms and potentially mitigate the progression of OA. We will also explore the application of genomic principles to the study of OA and the potential for the discovery of OA phenotypes that can motivate more precise patient-driven treatments.

Emerging technology has a brilliant future: the CRISPR-Cas system for senescence, inflammation, and cartilage repair in osteoarthritis

Exploration of CRISPR/Cas9-based gene editing as therapy for osteoarthritis

“Genetic scissors” CRISPR/Cas9 genome editing cutting-edge biocarrier technology for bone and cartilage repair

Engineering approaches for RNA-based and cell-based osteoarthritis therapies

New treatment for osteoarthritis: Gene therapy

Mesenchymal stem cell-based treatment for cartilage defects in osteoarthritis

CRISPR-mediated Sox9 activation and RelA inhibition enhance cell therapy for osteoarthritis

CRISPR innovations in tissue engineering and gene editing

CRISPR/Cas9 Mechanism and Applications Progression

Current Research on Pharmacologic and Regenerative Therapies for Osteoarthritis

Progress and Application of CRISPR/Cas Technology in Biological and Biomedical Investigation.

Therapeutic Perspectives for Inflammation and Senescence in Osteoarthritis Using Mesenchymal Stem Cells, Mesenchymal Stem Cell-Derived Extracellular Vesicles and Senolytic Agents

CRISPR/Cas: a Nobel Prize award-winning precise genome editing technology for gene therapy and crop improvement

Advances in Stem Cell-Based Therapies in the Treatment of Osteoarthritis

The Potential of CRISPR/Cas9 Gene Editing as a Treatment Strategy for Inherited Diseases

Advances in targeted therapies for age-related osteoarthritis: A comprehensive review of current research

Recent Advances in Pharmacological Intervention of Osteoarthritis: A Biological Aspect

CRISPR/Cas system: An emerging technology in stem cell research

The application and therapeutic potential of CRISPR/Cas9 technology in diseases

Targeting of chondrocyte plasticity via connexin43 modulation attenuates cellular senescence and fosters a pro-regenerative environment in osteoarthritis

CRISPR/Cas9 Technology as an Emerging Tool for Targeting Amyotrophic Lateral Sclerosis (ALS)